The inclusion of tildrakizumab injection in NRDL will further boost Sun Pharma commercialisation efforts globally. NRDL is a list of drugs fully or partially reimbursed by the national basic health insurance in China covering 96% of the population or more than 1.36 billion people.

Related Keywords

Mumbai , Maharashtra , India , China , Sun Pharma , National Medical Products Administration , China Medical System Holdings Limited , China National Reimbursement Drug List , National Reimbursement Drug List , Tildrakizumab , Specialty Drug , China Reimbursement List , Nrdl ,